Despite the prevailing narrative of geopolitical 'de-risking,' global institutional investors are intensifying their scrutiny of the Chinese market, shifting their focus from consumer internet giants to the 'hard-tech' sectors favored by Beijing’s industrial policy. Recent data through June 19, 2026, reveals a surge in site visits and research activity by foreign funds targeting A-share companies. This uptick in due diligence suggests that international capital is positioning itself for a new era of Chinese growth centered on domestic self-reliance and technological sovereignty.
The semiconductor industry has emerged as the primary theater of interest. Firms such as Montage Technology and CR Micro have seen a flurry of inquiries as investors weigh their potential to navigate US-led export controls. The logic is clear: as China aggressively builds an end-to-end domestic chip supply chain, the companies providing the 'picks and shovels' for this infrastructure represent a long-term strategic play that transcends temporary trade friction.
Beyond silicon, the healthcare sector is undergoing a similar re-evaluation. Foreign interest is coalescing around high-end medical imaging and innovative drug developers like BeiGene and Mindray. As China’s demographic challenges mount, Beijing is prioritizing the localization of expensive medical technology to reduce healthcare costs, creating a state-sanctioned growth path for domestic champions that global portfolios are now eager to capture.
Finally, the 'AI-plus' manufacturing sector is attracting significant attention. Companies involved in high-end equipment manufacturing and the integration of artificial intelligence into industrial processes are being tracked as barometers of China’s broader economic transition. For global asset managers, these surveys serve as a critical lead indicator for future capital allocation, signaling a transition from speculative trading toward a more structural, policy-aligned investment strategy in the world's second-largest economy.